FHIT Antibodies

FHIT (Fragile Histidine Triad) is a tumor suppressor gene involved in the regulation of apoptosis and genomic stability. The FHIT protein plays a crucial role in preventing cancer development by regulating DNA damage response and promoting programmed cell death in response to cellular stress. FHIT is located at a common fragile site in the human genome, which is often deleted or altered in various cancers, including lung, breast, and gastrointestinal cancers.

Content

FHIT antibodies are designed to specifically detect FHIT protein levels in various biological samples, including tissue lysates, cultured cells, and tumor biopsies. These antibodies are widely used in immunohistochemistry (IHC), Western blotting, immunoprecipitation (IP), and ELISA to study FHIT expression and its functional role in tumor suppression.

Applications

• Cancer Research: FHIT is frequently altered in many cancers, making FHIT antibodies essential tools for studying its role as a tumor suppressor. FHIT antibodies are used to assess FHIT expression in tumor versus normal tissues, investigate its involvement in cancer progression, and explore therapeutic strategies aimed at restoring FHIT function in cancer cells.
• Apoptosis Studies: FHIT plays a significant role in regulating apoptosis, particularly in response to DNA damage. FHIT antibodies allow researchers to study the involvement of FHIT in apoptotic pathways and how its loss contributes to uncontrolled cell growth and resistance to cell death in cancer cells.
• DNA Damage Response: The loss of FHIT function has been linked to genomic instability, a hallmark of cancer. Antibodies against FHIT are used to investigate how this protein contributes to maintaining genomic stability by regulating the response to DNA damage, making it a crucial target for understanding how its loss drives carcinogenesis.
• Tumor Suppressor Pathways: FHIT interacts with other tumor suppressor proteins and signaling pathways that control cell proliferation and apoptosis. By using FHIT antibodies, researchers can explore these interactions and map out the tumor suppressor networks disrupted in cancer.
• Prognostic Marker: FHIT expression levels are often correlated with tumor grade and patient prognosis. FHIT antibodies are used in clinical studies to evaluate FHIT as a potential prognostic marker, helping to identify patients who may benefit from targeted therapies aimed at restoring tumor suppressor activity.

By utilizing FHIT antibodies in research, scientists can gain deeper insights into the role of FHIT in cancer biology, apoptosis regulation, and genomic stability, providing opportunities to develop novel cancer therapies targeting this key tumor suppressor pathway.